I think that market today value very little bt new deal (if there are no significant up front and near milestones payment), so NBIX isn't excluded.
However, after DHEA is gone, maybe somebody will start looking on what is left. And, they will be surprised with what they find. The value of only two programs in PII (CRF-r antagonist<J&J>, and APL antagonist<Novartis>), without epilepsy drug, toxin, obesity APL agonist, EAAts, IGF-bp3 antagonist, melanocortin receptors,..., exceeded today NBIX technology value by at lest two-three fold.
Maybe today article in BG has something to do with small move.
boston.com
<<Much of the excitement comes from the growing recognition that an almond-sized brain structure called the amygdala plays a central role in the processing of fear and almost certainly in depression and chronic anxiety as well.
The amygdala is rich in receptors for substance P, a brain chemical originally thought to transmit pain signals but now believed to be more important for depression and anxiety. The amygdala is also rich in receptors for CRH, the stress hormone.
At the same time that drug makers are scrambling to find drugs to block CRH and substance P, they are scurrying to improve the current SSRIs, which combat depression and anxiety by increasing levels of a brain chemical called serotonin in the synapse, or space, between nerve cells.>>
So who has lead in CRF?
And, after Substance P inhibitors(Merck) now has significant delay in further clinical trials.
I bought initially (in 98) NBIX at 8 5/8 and am considering myself very lucky to be able to buy additional shares on the way down and recently below 5.
Miljenko
|
